Hebo Pharmaceutical-B announced that revenue for the first half of 2026 was US$122 million, compared to US$101 million for the same period in 2025; profit for the period was US$64.851 million, compared to US$72.99 million for the same period in 2025. The company won an overall victory in the patent infringement lawsuit brought against Amgen and its subsidiaries through its wholly-owned subsidiary Harbour Antibodies. The US Delaware federal district court jury ruled that Amgen deliberately infringed and that the patent was valid, and the company is entitled to $20203,704 in damages.
Zhitongcaijing · 1d ago
Share
Listen to the news
Hebo Pharmaceutical-B announced that revenue for the first half of 2026 was US$122 million, compared to US$101 million for the same period in 2025; profit for the period was US$64.851 million, compared to US$72.99 million for the same period in 2025. The company won an overall victory in the patent infringement lawsuit brought against Amgen and its subsidiaries through its wholly-owned subsidiary Harbour Antibodies. The US Delaware federal district court jury ruled that Amgen deliberately infringed and that the patent was valid, and the company is entitled to $20203,704 in damages.
Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.
What's Trending